trifluridine has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferdous, T; Harada, K; Mishima, K | 1 |
| Emura, T; Fujioka, A; Fukushima, M; Ohshimo, H; Suzuki, N | 1 |
2 other study(ies) available for trifluridine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Efficacy of a Novel Oral Chemotherapeutic Agent, TAS-102, Against Human Oral Squamous Cell Carcinoma Cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Combinations; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mouth Neoplasms; Neovascularization, Pathologic; NF-kappa B; Pyrrolidines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Thymine; Trifluridine; Xenograft Model Antitumor Assays | 2021 |
Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Humans; Macaca fascicularis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Thymidine; Thymidine Phosphorylase; Time Factors; Trifluridine; Xenograft Model Antitumor Assays | 2005 |